Congenital factor V deficiency from compound heterozygous mutations with a novel variant c.2426del (p.Pro809Hisfs2) in the F5 gene: A case report

被引:2
作者
Park, Chang-Hun [1 ]
Park, Min-Seung [2 ]
Lee, Ki-O [3 ]
Kim, Sun-Hee [2 ]
Park, Young Shil [4 ]
Kim, Hee-Jin [2 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Dept Lab Med & Genet, Chang Won, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Lab Med & Genet, 81 Irwon Ro, Seoul 06351, South Korea
[3] Samsung Med Ctr, Samsung Biomed Res Inst, Seoul, South Korea
[4] Kyung Hee Univ Hosp Gangdong, Dept Pediat, 892 Dongnam Ro, Seoul 05278, South Korea
关键词
case report; F5; factor V deficiency; mutation; RARE BLEEDING DISORDERS;
D O I
10.1097/MD.0000000000018947
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction:Congenital factor V deficiency (FVD) is a rare bleeding disorder characterized by low or undetectable plasma factor V (FV) levels leading to mild to severe bleeding symptoms. Currently, more than 100 mutations have been reported in F5. We herein report a patient with FVD from mutations in the F5 gene.Patient concerns:A 52-year-old man with prolonged prothrombin time and activated partial thromboplastin time corrected by mixing test on preoperative screening. His past medical or family history was not remarkable.Diagnosis:Factor assays revealed a markedly reduced FV activity at 7%. Other factors were not decreased. DNA sequencing analysis to detect F5 gene mutations showed the patient was compound heterozygous for c.286G>C (p.Asp96His) and c.2426del (p.Pro809Hisfs2). Asp96His was previously described missense mutation and Pro809Hisfs2 was a novel deleterious mutation.Interventions:Fresh-frozen plasma was administered to supplement FV before surgery.Outcomes:Subsequent factor assays revealed temporarily increased FV activity at 33%.Conclusion:As was the case in our patient, genotype-phenotype correlations are poor in FVD, and molecular genetic test is necessary to confirm the diagnosis.
引用
收藏
页数:3
相关论文
共 12 条
  • [1] Inherited defects of coagulation factor V: the hemorrhagic side
    Asselta, R
    Tenchini, ML
    Duga, S
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (01) : 26 - 34
  • [2] Huang Dan-Dan, 2010, Zhonghua Xue Ye Xue Za Zhi, V31, P149
  • [3] Factor V deficiency: a concise review
    Huang, J. N.
    Koerper, M. A.
    [J]. HAEMOPHILIA, 2008, 14 (06) : 1164 - 1169
  • [4] Rare bleeding disorders - bleeding assessment tools, laboratory aspects and phenotype and therapy of FXI deficiency
    James, P.
    Salomon, O.
    Mikovic, D.
    Peyvandi, F.
    [J]. HAEMOPHILIA, 2014, 20 : 71 - 75
  • [5] Lak M, 1998, BRIT J HAEMATOL, V103, P1067
  • [6] Inherited and acquired factor V deficiency
    Lippi, Giuseppe
    Favaloro, Emmanuel J.
    Montagnana, Martina
    Manzato, Franco
    Guidi, Gian C.
    Franchini, Massimo
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2011, 22 (03) : 160 - 166
  • [7] Asp68His mutation in the A1 domain of human factor V causes impaired secretion and ineffective translocation
    Liu, H. -C.
    Shen, M. -C.
    Eng, H. -L.
    Wang, C. -H.
    Lin, T. -M.
    [J]. HAEMOPHILIA, 2014, 20 (04) : e318 - e326
  • [8] Factor V: a combination of Dr Jekyll and Mr Hyde
    Mann, KG
    Kalafatis, M
    [J]. BLOOD, 2003, 101 (01) : 20 - 30
  • [9] Genetic Confirmation of Congenital Factor V Deficiency in Korean Patients
    Park, Chang-Hun
    Yoo, Kiyoung
    Lee, Ki-O
    Kim, Sun-Hee
    Sung, Ki-Woong
    Kim, Hee-Jin
    [J]. ANNALS OF LABORATORY MEDICINE, 2016, 36 (02) : 182 - 184
  • [10] Three-dimensional model of coagulation factor Va bound to activated protein C
    Pellequer, JL
    Gale, AJ
    Getzoff, ED
    Griffin, JH
    [J]. THROMBOSIS AND HAEMOSTASIS, 2000, 84 (05) : 849 - 857